View Item 

Show simple item record

Revisiting mycophenolate mofetil for steroid‐refractory acute graft‐versus‐host disease: Is higher dosing effective in children?

dc.contributor.authorLevine, John E.en_US
dc.date.accessioned2015-08-05T16:47:48Z
dc.date.available2016-10-10T14:50:23Zen
dc.date.issued2015-09en_US
dc.identifier.citationLevine, John E. (2015). "Revisiting mycophenolate mofetil for steroid‐refractory acute graft‐versus‐host disease: Is higher dosing effective in children?." Pediatric Transplantation 19(6): 582-583.en_US
dc.identifier.issn1397-3142en_US
dc.identifier.issn1399-3046en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/112292
dc.publisherWiley Periodicals, Inc.en_US
dc.titleRevisiting mycophenolate mofetil for steroid‐refractory acute graft‐versus‐host disease: Is higher dosing effective in children?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/112292/1/petr12536.pdf
dc.identifier.doi10.1111/petr.12536en_US
dc.identifier.sourcePediatric Transplantationen_US
dc.identifier.citedreferenceMacMillan ML, Davies SM, Nelson GO, et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008: 14 ( Suppl ): 16 – 22.en_US
dc.identifier.citedreferenceDavies SM, Wang D, Wang T, et al. Recent decrease in acute graft‐versus‐host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 2009: 15: 360 – 366.en_US
dc.identifier.citedreferenceFerrara JL, Levine JE, Reddy P, Holler E. Graft‐versus‐host disease. Lancet 2009: 373: 1550 – 1561.en_US
dc.identifier.citedreferenceLevine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft‐versus‐host disease based on biomarkers: A multicenter study. Lancet Haematol 2015: 2: e21 – e29.en_US
dc.identifier.citedreferenceInagaki J, Kodama Y, Fukano R, Noguchi M, Okamura J. Mycophenolate mofetil for treatment of steroid‐refractory acute graft‐versus‐host disease after pediatric hematopoietic stem cell transplantation. Pediatr Transplant 2015: 19.en_US
dc.identifier.citedreferenceMartin PJ, Rizzo JD, Wingard JR, et al. First‐ and second‐line systemic treatment of acute graft‐versus‐host disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012: 18: 1150 – 1163.en_US
dc.identifier.citedreferenceHarnicar S, Ponce DM, Hilden P, et al. Intensified mycophenolate mofetil dosing and higher mycophenolic acid trough levels reduce severe acute graft‐versus‐host disease after double‐unit cord blood transplantation. Biol Blood Marrow Transplant 2015: 21: 920 – 925.en_US
dc.identifier.citedreferenceJacobson PA, Huang J, Wu J, et al. Mycophenolate pharmacokinetics and association with response to acute graft‐versus‐host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 2010: 16: 421 – 429.en_US
dc.identifier.citedreferenceBolaños‐Meade J, Logan BR, Alousi AM, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood 2014: 124: 3221 – 3227.en_US
dc.identifier.citedreferenceMacMillan ML, Robin M, Harris AC, et al. A refined risk score for acute graft‐versus‐host disease that predicts response to initial therapy, survival, and transplant‐related mortality. Biol Blood Marrow Transplant 2015: 21: 761 – 767.en_US
dc.identifier.citedreferenceFerrara JL, Harris AC, Greenson JK, et al. Regenerating islet‐derived 3‐alpha is a biomarker of gastrointestinal graft‐versus‐host disease. Blood 2011: 118: 6702 – 6708.en_US
dc.identifier.citedreferenceXiao B, Wang Y, Li W, et al. Plasma microRNA signature as a noninvasive biomarker for acute graft‐versus‐host disease. Blood 2013: 122: 3365 – 3375.en_US
dc.identifier.citedreferenceVander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy‐resistant graft‐versus‐host disease and death. N Engl J Med 2013: 369: 529 – 539.en_US
dc.identifier.citedreferenceHahn T, McCarthy PL Jr, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013: 31: 2437 – 2449.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
petr12536.pdf
Size:
54.52KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.